Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
17. Dezember 2024 07:00 ET
|
Tenaya Therapeutics, Inc.
TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
16. Dezember 2024 16:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
25. November 2024 08:30 ET
|
Tenaya Therapeutics, Inc.
TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease RIDGE-1 Currently Enrolling at Six Centers;...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19. November 2024 08:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
06. November 2024 16:05 ET
|
Tenaya Therapeutics, Inc.
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1...
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
17. Oktober 2024 16:30 ET
|
Tenaya Therapeutics, Inc.
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024...
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
03. September 2024 08:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08. August 2024 16:05 ET
|
Tenaya Therapeutics, Inc.
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of...
Tenaya Therapeutics Announces Research Leadership Updates
27. Juni 2024 17:00 ET
|
Tenaya Therapeutics, Inc.
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic Therapy Expert Barry J. Byrne, M.D., Ph.D.,...
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
18. Juni 2024 16:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...